human cells
in biomedicine and biotechnolgy

human cells
as in vitro test systems

Highly differentiated human cells are of ever increasing importance as in vitro test systems in various fields of biomedicine, toxicology and biotechnology. Although normal somatic cells maintain a phenotype similar to the corresponding cells in vivo, the application of these cells is limited due to their finite life span. On the contrary, tumor cells can be grown indefinitely but have lost essential characteristics. These disadvantages of normal and tumor cell lines lead to the fact that most in vitro bioassays can not be reproduced and standardized.
In order to circumvent these limitations, Evercyte has focused on the establishment of cell lines that can be grown without growth arrest while maintaining a phenotype that resembles that of the corresponding primary / normal cells. This is achieved by ectopic expression of the catalytic subunit of human telomerase in primary cells followed by a detailed characterization of the cellular phenotype.Moreover, in order to expand the number of available cell types from healthy or diseased humans, Evercyte uses urine as novel innovative cell source. Urine-derived cells can be reprogrammed towards inducted pluripotent stem cells for subsequent differentiation into specific cell types that are difficult to isolate from human tissues.

human cells
as innovative cell factories

Due to their capacity to transport proteins, lipids as well as nucleic acids extracellular vesicles (EVs) / exosomes play an important role in cellular communication and have gained ever increasing importance in the fields of regenerative medicine, anti-tumor therapy or immunotherapy. Specifically, EVs secreted from human stem cells have been reported to be equally effective as the transplanted cells in various disease models. Therefore, Evercyte has put a focus on the development of human cells that produce EVs with therapeutic activity.
Additionally, human highly specialized cells qualify for production of recombinant proteins or vaccines. Today, more than 60% of recombinant proteins used for therapeutic applications are produced in mammalian cells, which is due to appropriate protein folding, assembly and posttranslational modification, factors that are major determinants for the biological activity and product quality. However, most commonly used mammalian cell factories have e.g. abnormal glycosylation patterns and thus may produce protein isoforms that differ from those synthesized in normal cells. Furthermore, differences in the glycosylation patterns produced by cells from different tissues accentuate the need for selection and establishment of novel host cell lines.
Evercyte´s telomerized cell lines show stable growth characteristics and phenotypes and have a high potential for production of complex biopharmaceuticals. Evercyte provides cell factories that allow production of extracellular vesicles also for clinical application. Moreover, we offer customer-tailored cell line development services.